{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:04:03Z","timestamp":1790129043274,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008572","name":"University of Ottawa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012161","name":"Faculty of Medicine, University of British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurot.2026.e00978","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:29:16Z","timestamp":1785749356000},"page":"e00978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner"],"prefix":"10.1016","volume":"23","author":[{"given":"Shatha A.","family":"Atieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim\u00e8ne","family":"Fahmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Ravel-Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Jasmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp.2008.158261","article-title":"The myotonic dystrophies: diagnosis and management","volume":"81","author":"Turner","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.neurot.2026.e00978_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00439-005-1298-8","article-title":"Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec","volume":"117","author":"Yotova","year":"2005","journal-title":"Hum Genet"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2019 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"issue":"5049","key":"10.1016\/j.neurot.2026.e00978_bib4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1126\/science.1546326","article-title":"An unstable triplet repeat in a gene related to myotonic muscular dystrophy","volume":"255","author":"Fu","year":"1992","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00978_bib5","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/nar\/27.17.3534","article-title":"Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein","volume":"27","author":"Michalowski","year":"1999","journal-title":"Nucleic Acids Res"},{"issue":"5485","key":"10.1016\/j.neurot.2026.e00978_bib6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.289.5485.1769","article-title":"Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat","volume":"289","author":"Mankodi","year":"2000","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.neurot.2026.e00978_bib8","unstructured":"Bird TD. Myotonic Dystrophy Type 1. 1999 Sep 17 [updated 2024 Nov 14]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132026. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1165\/"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000524734","article-title":"Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis","volume":"56","author":"Liao","year":"2022","journal-title":"Neuroepidemiology"},{"issue":"5049","key":"10.1016\/j.neurot.2026.e00978_bib10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.1546325","article-title":"Myotonic dystrophy mutation: an unstable CTG repeat in the 3\u2032 untranslated region of the gene","volume":"255","author":"Mahadevan","year":"1992","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00978_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1083\/jcb.128.6.995","article-title":"Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues","volume":"128","author":"Taneja","year":"1995","journal-title":"J Cell Biol"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00978_bib12","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1073\/pnas.94.14.7388","article-title":"Expansion of a CUG trinucleotide repeat in the 3\u2032 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts","volume":"94","author":"Davis","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"10.1016\/j.neurot.2026.e00978_bib13","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","article-title":"Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy","volume":"19","author":"Miller","year":"2000","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00978_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/genes11091109","article-title":"An overview of alternative splicing defects implicated in myotonic dystrophy type I","volume":"11","author":"L\u00f3pez-Mart\u00ednez","year":"2020","journal-title":"Genes (Basel)"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00978_bib15","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1038\/sj.emboj.7600300","article-title":"Muscleblind proteins regulate alternative splicing","volume":"23","author":"Ho","year":"2004","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2026.111219","article-title":"Disruptions of cell signaling pathways in myotonic dystrophy type 1 (DM1) skeletal muscle, their pathogenic impact and potential for combinatorial therapeutics","volume":"302","author":"Ravel-Chapuis","year":"2026","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S1355838200991544","article-title":"Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR","volume":"6","author":"Tian","year":"2000","journal-title":"RNA"},{"issue":"24","key":"10.1016\/j.neurot.2026.e00978_bib18","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00978_bib20","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1172\/JCI64081","article-title":"GSK3\u03b2 mediates muscle pathology in myotonic dystrophy","volume":"122","author":"Jones","year":"2012","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00978_bib21","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/hmg\/ddu617","article-title":"TWEAK\/Fn14, a pathway and novel therapeutic target in myotonic dystrophy","volume":"24","author":"Yadava","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1172\/JCI89616","article-title":"Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type I","volume":"127","author":"Brockhoff","year":"2017","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00978_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41419-020-02756-8","article-title":"MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00978_bib24","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/hmg\/ddx109","article-title":"Misregulation of calcium-handling proteins promotes hyperactivation of calcineurin\u2013NFAT signaling in skeletal muscle of DM1 mice","volume":"26","author":"Ravel-Chapuis","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00978_bib25","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1093\/hmg\/ddy245","article-title":"Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles","volume":"27","author":"Ravel-Chapuis","year":"2018","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00978_bib26","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/v4112598","article-title":"dsRNA-Dependent protein kinase PKR and its role in stress, signaling and HCV infection","volume":"4","author":"Dabo","year":"2012","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00978_bib27","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/db07-1769","article-title":"Protein kinase C function in muscle, liver, and \u03b2-Cells and its therapeutic implications for type 2 diabetes","volume":"57","author":"Schmitz-Peiffer","year":"2008","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.yjmcc.2011.07.013","article-title":"PKC-delta and PKC-epsilon: foes of the same family or strangers?","volume":"51","author":"Duquesnes","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.neurot.2026.e00978_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.neurot.2026.e00978_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.12703\/r\/11-32","article-title":"The role of mTORC1 in the regulation of skeletal muscle mass","volume":"11","author":"Bodine","year":"2022","journal-title":"Fac Rev"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00978_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.tem.2015.02.009","article-title":"Expanding roles for AMPK in skeletal muscle plasticity","volume":"26","author":"Mounier","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.neurot.2026.e00978_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00018","article-title":"TWEAK\/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction","volume":"5","author":"Sato","year":"2014","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00978_bib35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00109-008-0308-4","article-title":"NF-\u03baB signaling in skeletal muscle: prospects for intervention in muscle diseases","volume":"86","author":"Mourkioti","year":"2008","journal-title":"J Mol Med (Berl)"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00978_bib36","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.biocel.2013.06.029","article-title":"Calcineurin: a poorly understood regulator of muscle mass","volume":"45","author":"Hudson","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"issue":"Pt 21","key":"10.1016\/j.neurot.2026.e00978_bib37","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1113\/jphysiol.2011.212860","article-title":"The role of in vivo Ca2+ signals acting on Ca2+\u2013calmodulin-dependent proteins for skeletal muscle plasticity","volume":"589","author":"Tavi","year":"2011","journal-title":"J Physiol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00978_bib38","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1101\/gad.12.16.2499","article-title":"A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type","volume":"12","author":"Chin","year":"1998","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/hmg\/ddac222","article-title":"Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner","volume":"32","author":"Misquitta","year":"2023","journal-title":"Hum Mol Genet"},{"issue":"23","key":"10.1016\/j.neurot.2026.e00978_bib40","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202401145RR","article-title":"The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscle","volume":"38","author":"Ravel-Chapuis","year":"2024","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00978_bib41","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/brain\/awy231","article-title":"Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial","volume":"141","author":"Bassez","year":"2018","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00978_bib42","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.4103\/1673-5374.276336","article-title":"Resveratrol corrects aberrant splicing of RYR1 pre-mRNA and Ca2+ signal in myotonic dystrophy type 1 myotubes","volume":"15","author":"Santoro","year":"2020","journal-title":"Neural Regen Res"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00978_bib43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.braindev.2014.11.001","article-title":"Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts","volume":"37","author":"Takarada","year":"2015","journal-title":"Brain Dev"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00978_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/biology9090252","article-title":"Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery","volume":"9","author":"Tran","year":"2020","journal-title":"Biology"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1017\/S000711450783176X","article-title":"Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats","volume":"99","author":"Sridhar","year":"2008","journal-title":"Br J Nutr"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0007114521001082","article-title":"Bitter melon fruit extract enhances intracellular ATP production and insulin secretion from rat pancreatic \u03b2-cells","volume":"127","author":"Shimada","year":"2022","journal-title":"Br J Nutr"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0168-8227(98)00022-9","article-title":"Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat","volume":"40","author":"Ahmed","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0378-8741(86)90116-9","article-title":"Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes","volume":"17","author":"Welihinda","year":"1986","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3177\/jnsv.47.340","article-title":"Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice","volume":"47","author":"Miura","year":"2001","journal-title":"J Nutr Sci Vitaminol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/phrs.1996.0001","article-title":"Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes","volume":"33","author":"Sarkar","year":"1996","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2222-1808(13)60052-3","article-title":"Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency","volume":"3","author":"Joseph","year":"2013","journal-title":"Asian Pac J Trop Dis"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.diabres.2008.04.023","article-title":"Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet","volume":"81","author":"Shih","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.neurot.2026.e00978_bib53","doi-asserted-by":"crossref","first-page":"123173","DOI":"10.1016\/j.ijbiomac.2023.123173","article-title":"New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: a review","volume":"231","author":"Bora","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.neurot.2026.e00978_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.prmcm.2023.100226","article-title":"Exploring the phytochemistry, pharmacognostic properties, and pharmacological activities of medically important plant momordica charantia","volume":"6","author":"Mukherjee","year":"2023","journal-title":"Pharmacol Res - Modern Chin Med"},{"key":"10.1016\/j.neurot.2026.e00978_bib55","doi-asserted-by":"crossref","first-page":"116154","DOI":"10.1016\/j.jep.2023.116154","article-title":"Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD\/STZ-induced type 2 diabetic rats","volume":"306","author":"Sun","year":"2023","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.chembiol.2008.01.013","article-title":"Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway","volume":"15","author":"Tan","year":"2008","journal-title":"Chem Biol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00978_bib57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/1940-6207.CAPR-17-0046","article-title":"Bitter Melon enhances natural killer\u2013mediated toxicity against head and neck cancer cells","volume":"10","author":"Bhattacharya","year":"2017","journal-title":"Cancer Prev Res"},{"issue":"22","key":"10.1016\/j.neurot.2026.e00978_bib58","doi-asserted-by":"crossref","first-page":"33202","DOI":"10.18632\/oncotarget.8898","article-title":"Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth","volume":"7","author":"Bhattacharya","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib59","first-page":"5833","article-title":"MAP30 promotes apoptosis of U251 and U87 cells by suppressing the LGR5 and Wnt\/\u03b2-catenin signaling pathway, and enhancing Smac expression","volume":"15","author":"Jiang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.neurot.2026.e00978_bib60","doi-asserted-by":"crossref","first-page":"702869","DOI":"10.1155\/2013\/702869","article-title":"Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy","volume":"2013","author":"Kwatra","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.neurot.2026.e00978_bib61","doi-asserted-by":"crossref","unstructured":"Fang EF, Froetscher L, Scheibye-Knudsen M, Bohr VA, Wong JH, Ng TB. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia). Curr Protein Pept Sci. 2019;20(3):296\u2013301. doi:10.2174\/1389203719666180622095800 PubMed PMID: 29932035; PubMed Central PMCID: PMC6486373.","DOI":"10.2174\/1389203719666180622095800"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12964-019-0447-y","article-title":"Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract","volume":"17","author":"Sur","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.neurot.2026.e00978_bib63","doi-asserted-by":"crossref","first-page":"2821597","DOI":"10.1155\/2019\/2821597","article-title":"Momordica charantia (Indian and Chinese bitter Melon) extracts inducing apoptosis in human lung cancer cell line A549 via ROS-mediated mitochodria injury","volume":"2019","author":"Thiagarajan","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib64","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.3390\/ijms24054643","article-title":"The effects of Momordica charantia on type 2 diabetes mellitus and Alzheimer\u2019s disease","volume":"24","author":"Richter","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib65","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/87559129.2021.1923733","article-title":"Bitter melon and diabetes mellitus","volume":"39","author":"Gao","year":"2023","journal-title":"Food Rev Int"},{"issue":"14","key":"10.1016\/j.neurot.2026.e00978_bib66","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1113\/JP282725","article-title":"Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients","volume":"600","author":"Ravel-Chapuis","year":"2022","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062309","article-title":"Activation of AMPK by bitter melon triterpenoids involves CaMKK\u03b2","volume":"8","author":"Iseli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00978_bib68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fneur.2018.00368","article-title":"Abnormalities in skeletal muscle myogenesis, growth, and regeneration in myotonic dystrophy","volume":"9","author":"Andr\u00e9","year":"2018","journal-title":"Front Neurol"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00978_bib69","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/hmg\/ddl132","article-title":"Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy","volume":"15","author":"Lin","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00978_bib70","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nm.2374","article-title":"Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy","volume":"17","author":"Fugier","year":"2011","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00978_bib71","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/emmm.201303275","article-title":"Compound loss of muscleblind-like function in myotonic dystrophy","volume":"5","author":"Lee","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00978_bib72","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1093\/nar\/gkp681","article-title":"MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1","volume":"37","author":"Kino","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.neurot.2026.e00978_bib73","series-title":"What DM treatment or therapies are available?","year":"2026"},{"key":"10.1016\/j.neurot.2026.e00978_bib74","series-title":"What it Is, symptoms, types & treatment","author":"Dystrophy","year":"2026"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib75","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/jnr.22551","article-title":"Perspectives on gene therapy in myotonic dystrophy type 1","volume":"89","author":"Maga\u00f1a","year":"2011","journal-title":"J Neurosci Res"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00978_bib76","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.drudis.2018.08.004","article-title":"RNA-mediated therapies in myotonic dystrophy","volume":"23","author":"Overby","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.neurot.2026.e00978_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00349","article-title":"Small molecules which improve pathogenesis of myotonic dystrophy type 1","volume":"9","author":"L\u00f3pez-Morat\u00f3","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurot.2026.e00978_bib78","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pediatrneurol.2020.08.001","article-title":"A phase 2 study of AMO-02 (tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1)","volume":"112","author":"Horrigan","year":"2020","journal-title":"Pediatr Neurol"},{"issue":"33","key":"10.1016\/j.neurot.2026.e00978_bib79","doi-asserted-by":"crossref","first-page":"17165","DOI":"10.1074\/jbc.M115.710616","article-title":"Identification of plant-derived alkaloids with therapeutic potential for myotonic dystrophy type I","volume":"291","author":"Herrendorff","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurot.2026.e00978_bib80","doi-asserted-by":"crossref","unstructured":"Mishra SK, Hicks SM, Frias JA, Vangaveti S, Nakamori M, Cleary JD, et al. Quercetin selectively reduces expanded repeat RNA levels in models of myotonic dystrophy. bioRxiv [Preprint]. 2023 [cited 2026 Jul 26]:2023.02.02.526846. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2023.02.02.526846v1","DOI":"10.1101\/2023.02.02.526846"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00978_bib81","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.3390\/ijms24129820","article-title":"Natural compound boldine lessens myotonic dystrophy type 1 phenotypes in DM1 drosophila models, patient-derived cell lines, and HSALR mice","volume":"24","author":"\u00c1lvarez-Abril","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurot.2026.e00978_bib82","doi-asserted-by":"crossref","first-page":"123659","DOI":"10.1016\/j.lfs.2025.123659","article-title":"Singh MD.Gender disparities in myotonic dystrophy 1","volume":"373","author":"Chakraborty","year":"2025","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148264","article-title":"Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study","volume":"11","author":"Dogan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00978_bib84","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fneur.2020.00394","article-title":"High prevalence and gender-related differences of gastrointestinal manifestations in a cohort of DM1 patients: a perspective, cross-sectional study","volume":"11","author":"Perna","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib85","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/cells10051095","article-title":"AICAr, a widely used AMPK activator with important AMPK-independent effects: a systematic review","volume":"10","author":"Vi\u0161nji\u0107","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00978_bib86","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41684-025-01506-7","article-title":"Use of HSALR female mice as a model for the study of myotonic dystrophy type I","volume":"54","author":"Carrascosa-S\u00e0ez","year":"2025","journal-title":"Lab Anim"},{"issue":"13","key":"10.1016\/j.neurot.2026.e00978_bib87","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/hmg\/ddaa111","article-title":"Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features","volume":"29","author":"Crawford Parks","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.neurot.2026.e00978_bib88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2022.07.073","article-title":"The RNA-binding proteins CELF1 and ELAVL1 cooperatively control the alternative splicing of CD44","volume":"626","author":"David","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.neurot.2026.e00978_bib89","doi-asserted-by":"crossref","unstructured":"David G, Deschamps S, Padilla-Parra S, Tramier M, Audic Y, Paillard L. The RNA-binding proteins CELF1 and ELAVL1 cooperatively control alternative splicing. bioRxiv [Preprint]. 2018 [cited 2026 Mar 30]:373704. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/373704v1.","DOI":"10.1101\/373704"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00978_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006316","article-title":"Dose-dependent regulation of alternative splicing by MBNL proteins reveals biomarkers for myotonic dystrophy","volume":"12","author":"Wagner","year":"2016","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00978_bib91","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nsmb.1720","article-title":"Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy","volume":"17","author":"Du","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00978_bib92","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1101\/gr.184390.114","article-title":"Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins","volume":"25","author":"Wang","year":"2015","journal-title":"Genome Res"},{"issue":"26","key":"10.1016\/j.neurot.2026.e00978_bib93","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.1074\/jbc.RA118.002733","article-title":"The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice","volume":"293","author":"Sasaki","year":"2018","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.123.001613","article-title":"Post-transcriptional and epigenetic regulation of estrogen signaling","volume":"386","author":"Cignarella","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.neurot.2026.e00978_bib95","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1021\/jf200418g","article-title":"Isolation and identification of cucurbitane-type triterpenoids with partial agonist\/antagonist potential for estrogen receptors from Momordica charantia","volume":"59","author":"Hsu","year":"2011","journal-title":"J Agric Food Chem"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib96","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150074","article-title":"Oestrogen receptors interact with the \u03b1-catalytic subunit of AMP-activated protein kinase","volume":"35","author":"Lipovka","year":"2015","journal-title":"Biosci Rep"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00978_bib97","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.molmed.2013.07.002","article-title":"AMP-activated protein kinase at the nexus of therapeutic skeletal muscle plasticity in Duchenne muscular dystrophy","volume":"19","author":"Ljubicic","year":"2013","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00978_bib98","doi-asserted-by":"crossref","first-page":"C110","DOI":"10.1152\/ajpcell.00183.2011","article-title":"Chronic AMPK stimulation attenuates adaptive signaling in dystrophic skeletal muscle","volume":"302","author":"Ljubicic","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00978_bib99","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tem.2018.02.010","article-title":"The role of AMPK in neuromuscular biology and disease","volume":"29","author":"Dial","year":"2018","journal-title":"Trends Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00978_bib100","first-page":"388","article-title":"The therapeutic potential of Wild Bitter Melon to ameliorate muscle atrophy in a murine model","volume":"14","author":"Seifi","year":"2024","journal-title":"Avicenna J Phytomed"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926001480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:09:14Z","timestamp":1790125754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926001480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1878747926001480"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00978","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bitter melon natural compound ameliorates the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00978"}}